Related references
Note: Only part of the references are listed.The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
Nicos Karasavvas et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2012)
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients
Alexandre Harari et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope
Mark S. de Souza et al.
JOURNAL OF IMMUNOLOGY (2012)
Attenuation of Vaccinia Tian Tan Strain by Removal of Viral TC7L-TK2L and TA35R Genes
Shifu Kan et al.
PLOS ONE (2012)
Statistical Interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: A Case Study for Statistical Issues in Efficacy Trials
Peter B. Gilbert et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Unpolarized Release of Vaccinia Virus and HIV Antigen by Colchicine Treatment Enhances Intranasal HIV Antigen Expression and Mucosal Humoral Responses
Yan Zhang et al.
PLOS ONE (2011)
A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations
Charani Ranasinghe et al.
VACCINE (2011)
Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2α
Simone Backes et al.
JOURNAL OF GENERAL VIROLOGY (2010)
Structure Function Studies of Vaccinia Virus Host Range Protein K1 Reveal a Novel Functional Surface for Ankyrin Repeat Proteins
Yongchao Li et al.
JOURNAL OF VIROLOGY (2010)
A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination
Xiaoxing Huang et al.
PLOS ONE (2009)
The effect of the vaccinia K1 protein on the PKR-eIF2α pathway in RK13 and HeLa cells
Kristen L. Willis et al.
VIROLOGY (2009)
Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes
Kaifan Dai et al.
VACCINE (2008)
Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7L
Xiangzhi Meng et al.
VIROLOGY (2008)
Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes
J. Weyer et al.
EPIDEMIOLOGY AND INFECTION (2008)
Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate
Patricia L. Earl et al.
VIROLOGY (2007)
The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes
Weijun Zhu et al.
JOURNAL OF VIROLOGICAL METHODS (2007)
Host range, growth property, and virulence of the smallpox vaccine: Vaccinia virus Tian Tan strain
Q Fang et al.
VIROLOGY (2005)
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
I Drexler et al.
CURRENT OPINION IN BIOTECHNOLOGY (2004)
Induction of HIV immunity in intranasal delivery of a MVA the genital tract after vector:: Enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule
MM Gherardi et al.
JOURNAL OF IMMUNOLOGY (2004)
Share Paper
